KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $20.3 million.

  • Arbutus Biopharma's Total Liabilities fell 3946.23% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 3946.23%. This contributed to the annual value of $34.3 million for FY2024, which is 1053.07% down from last year.
  • Per Arbutus Biopharma's latest filing, its Total Liabilities stood at $20.3 million for Q3 2025, which was down 3946.23% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Total Liabilities registered a high of $71.0 million during Q1 2022, and its lowest value of $20.3 million during Q2 2025.
  • Moreover, its 5-year median value for Total Liabilities was $37.6 million (2024), whereas its average is $40.8 million.
  • Per our database at Business Quant, Arbutus Biopharma's Total Liabilities skyrocketed by 12134.55% in 2022 and then plummeted by 4601.88% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Total Liabilities (Quarter) stood at $35.0 million in 2021, then skyrocketed by 67.11% to $58.6 million in 2022, then plummeted by 34.46% to $38.4 million in 2023, then fell by 10.53% to $34.3 million in 2024, then plummeted by 40.85% to $20.3 million in 2025.
  • Its Total Liabilities stands at $20.3 million for Q3 2025, versus $20.3 million for Q2 2025 and $37.9 million for Q1 2025.